|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INVS |
Gene summary for INVS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INVS | Gene ID | 27130 |
| Gene name | inversin | |
| Gene Alias | INV | |
| Cytomap | 9q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q2M1I4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27130 | INVS | CCI_1 | Human | Cervix | CC | 5.07e-06 | 7.12e-01 | 0.528 |
| 27130 | INVS | CCI_2 | Human | Cervix | CC | 5.71e-10 | 1.05e+00 | 0.5249 |
| 27130 | INVS | CCI_3 | Human | Cervix | CC | 9.23e-22 | 9.34e-01 | 0.516 |
| 27130 | INVS | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.13e-03 | 4.88e-01 | 0.3371 |
| 27130 | INVS | RNA-P17T-P17T-6 | Human | Lung | IAC | 4.71e-02 | 3.71e-01 | 0.3385 |
| 27130 | INVS | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.55e-04 | 4.65e-01 | 0.3329 |
| 27130 | INVS | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.44e-06 | 3.67e-01 | -0.2116 |
| 27130 | INVS | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.98e-07 | 7.41e-01 | -0.1941 |
| 27130 | INVS | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 9.09e-03 | 4.48e-01 | -0.2107 |
| 27130 | INVS | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.81e-06 | 3.91e-01 | -0.2119 |
| 27130 | INVS | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.10e-09 | 3.85e-01 | -0.0166 |
| 27130 | INVS | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.88e-06 | 2.61e-01 | -0.0132 |
| 27130 | INVS | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.23e-08 | 2.97e-01 | -0.013 |
| 27130 | INVS | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.47e-07 | 3.26e-01 | -0.0121 |
| 27130 | INVS | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 3.94e-06 | 5.13e-01 | -0.0961 |
| 27130 | INVS | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 8.10e-12 | 7.50e-01 | -0.0876 |
| 27130 | INVS | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 2.91e-02 | 4.37e-01 | -0.0822 |
| 27130 | INVS | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.35e-06 | 5.42e-01 | -0.0809 |
| 27130 | INVS | HTA12-15-2 | Human | Pancreas | PDAC | 4.54e-05 | 4.53e-01 | 0.2315 |
| 27130 | INVS | HTA12-23-1 | Human | Pancreas | PDAC | 3.69e-07 | 7.56e-01 | 0.3405 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
| GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
| GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
| GO:00301784 | Cervix | CC | negative regulation of Wnt signaling pathway | 35/2311 | 170/18723 | 1.52e-03 | 1.17e-02 | 35 |
| GO:00900901 | Cervix | CC | negative regulation of canonical Wnt signaling pathway | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
| GO:00160556 | Lung | IAC | Wnt signaling pathway | 95/2061 | 444/18723 | 1.13e-10 | 2.80e-08 | 95 |
| GO:01987386 | Lung | IAC | cell-cell signaling by wnt | 95/2061 | 446/18723 | 1.46e-10 | 3.48e-08 | 95 |
| GO:00301116 | Lung | IAC | regulation of Wnt signaling pathway | 74/2061 | 328/18723 | 1.14e-09 | 2.05e-07 | 74 |
| GO:00608286 | Lung | IAC | regulation of canonical Wnt signaling pathway | 54/2061 | 253/18723 | 1.25e-06 | 6.46e-05 | 54 |
| GO:00600706 | Lung | IAC | canonical Wnt signaling pathway | 61/2061 | 303/18723 | 2.09e-06 | 9.45e-05 | 61 |
| GO:00301783 | Lung | IAC | negative regulation of Wnt signaling pathway | 32/2061 | 170/18723 | 1.68e-03 | 1.76e-02 | 32 |
| GO:001605512 | Lung | AIS | Wnt signaling pathway | 91/1849 | 444/18723 | 9.38e-12 | 5.47e-09 | 91 |
| GO:019873812 | Lung | AIS | cell-cell signaling by wnt | 91/1849 | 446/18723 | 1.22e-11 | 6.13e-09 | 91 |
| GO:003011112 | Lung | AIS | regulation of Wnt signaling pathway | 70/1849 | 328/18723 | 3.81e-10 | 8.87e-08 | 70 |
| GO:006082812 | Lung | AIS | regulation of canonical Wnt signaling pathway | 52/1849 | 253/18723 | 2.40e-07 | 2.22e-05 | 52 |
| GO:006007012 | Lung | AIS | canonical Wnt signaling pathway | 59/1849 | 303/18723 | 2.73e-07 | 2.37e-05 | 59 |
| GO:003017811 | Lung | AIS | negative regulation of Wnt signaling pathway | 32/1849 | 170/18723 | 2.64e-04 | 5.05e-03 | 32 |
| GO:0090090 | Lung | AIS | negative regulation of canonical Wnt signaling pathway | 24/1849 | 137/18723 | 3.91e-03 | 3.59e-02 | 24 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa0431012 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa043108 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
| hsa0431011 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
| hsa0431021 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
| hsa0431031 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| INVS | SNV | Missense_Mutation | novel | c.2599N>A | p.Leu867Met | p.L867M | Q9Y283 | protein_coding | tolerated_low_confidence(0.24) | benign(0.006) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| INVS | SNV | Missense_Mutation | novel | c.2863N>A | p.Gln955Lys | p.Q955K | Q9Y283 | protein_coding | tolerated_low_confidence(0.11) | benign(0.022) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| INVS | SNV | Missense_Mutation | c.242N>C | p.Gln81Pro | p.Q81P | Q9Y283 | protein_coding | tolerated(0.11) | benign(0.366) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| INVS | SNV | Missense_Mutation | rs775894646 | c.665N>A | p.Arg222Gln | p.R222Q | Q9Y283 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| INVS | SNV | Missense_Mutation | novel | c.1159G>A | p.Asp387Asn | p.D387N | Q9Y283 | protein_coding | tolerated(0.09) | probably_damaging(0.98) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| INVS | SNV | Missense_Mutation | novel | c.2654C>T | p.Ser885Phe | p.S885F | Q9Y283 | protein_coding | deleterious_low_confidence(0.05) | benign(0) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| INVS | insertion | Frame_Shift_Ins | novel | c.2689_2690insCAGAACCCAAGGCCAAATGTGCCCCCCAGAAA | p.Glu897AlafsTer17 | p.E897Afs*17 | Q9Y283 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| INVS | insertion | Nonsense_Mutation | novel | c.526_527insCATAGTATTACATTTCAGTAAATAGAATCA | p.Gly176delinsAlaTerTyrTyrIleSerValAsnArgIleArg | p.G176delinsA*YYISVNRIR | Q9Y283 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| INVS | deletion | In_Frame_Del | novel | c.2099_2101delNNN | p.Ala701del | p.A701del | Q9Y283 | protein_coding | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| INVS | SNV | Missense_Mutation | novel | c.1606C>T | p.Arg536Cys | p.R536C | Q9Y283 | protein_coding | deleterious(0) | possibly_damaging(0.613) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 27130 | INVS | NA | duloxetine | DULOXETINE | 29407288 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |